These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23218887)

  • 1. The novel anticoagulants: the surgeons' prospective.
    Shamoun FE; Martin EN; Money SR
    Surgery; 2013 Mar; 153(3):303-7. PubMed ID: 23218887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
    Oberhofer E
    MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Akwaa F; Spyropoulos AC
    Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
    Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
    [No Abstract]   [Full Text] [Related]  

  • 5. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A; Daw HA; Crowther MA
    Cleve Clin J Med; 2013 Jul; 80(7):443-51. PubMed ID: 23821689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new oral anticoagulants.
    Breen KA; Hunt BJ
    Clin Med (Lond); 2011 Oct; 11(5):467-9. PubMed ID: 22034708
    [No Abstract]   [Full Text] [Related]  

  • 7. New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Schulman S
    Thromb Haemost; 2014 Apr; 111(4):575-82. PubMed ID: 24452881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
    Giorgi MA; Cohen Arazi H; Gonzalez CD; Di Girolamo G
    Expert Opin Pharmacother; 2011 Mar; 12(4):567-77. PubMed ID: 21254865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The new Anticoagulants - Relevant Facts for the GP].
    Asmis LM
    Praxis (Bern 1994); 2011 Aug; 100(16):971-6. PubMed ID: 21833915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Kasmeridis C; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative management of patients on new oral anticoagulants.
    Lai A; Davidson N; Galloway SW; Thachil J
    Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants].
    Roldán Schilling V; Vicente García V
    Med Clin (Barc); 2012 Oct; 139 Suppl 2():10-2. PubMed ID: 23498066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct oral anticoagulants in atrial fibrillation.
    Noll G; Noll S; Hürlimann D
    Semin Hematol; 2014 Apr; 51(2):139-46. PubMed ID: 24861798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation: a GP primer on the new oral anticoagulants.
    Brieger D
    Aust Fam Physician; 2014 May; 43(5):254-9. PubMed ID: 24791763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
    Dalén M; Hjemdahl P; Holmström M; Ivert T
    Lakartidningen; 2014 Jun 11-17; 111(24):1064-8. PubMed ID: 25129916
    [No Abstract]   [Full Text] [Related]  

  • 17. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J; Sullivan B; Khalabuda M; McBride BF
    J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.